Serva Energy

Serva Energy has developed a novel, highly promising reactor-based method to produce commercial quantities of Actinium‑225, a rare and potent alpha-emitting radioisotope used in next-generation targeted alpha therapies against cancer. Their technology transforms nuclear waste Radium‑226 into this life-saving isotope without problematic contaminants. The method has been validated by MIT’s Nuclear Research Laboratory and supported by Mayo Clinic experts. This innovation addresses critical supply shortages limiting development of TAT drugs globally. Besides healthcare applications, Serva also focuses on advancing safer, more efficient nuclear fuel technologies aimed at carbon-free energy solutions[1][2][3][5][6][8][10].